• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

ASCO GI 2025

January 23-25, 2025

  1. Durvalumab
  2. Durvalumab + Tremelimumab
  3. Trastuzumab Deruxtecan
  4. Sonesitatug vedotin (AZD0901)

pdf

Patterns of radiological progression in participants (pts) with embolization eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis

pdf

Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer

pdf

Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization‑eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis

pdf

Characterization of the real-world first line (1L) use of single dose tremelimumab regular interval durvalumab (STRIDE), for treatment of unresectable hepatocellular carcinoma (uHCC), using two electronic medical record (EMR) databases

pdf

Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US)

pdf

Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA)

pdf

Concordance between human epidermal growth factor receptor 2 (HER2) status by immunohistochemistry (IHC) and next generation sequencing (NGS) in tissue and blood samples from gastric and gastroesophageal junction cancers (GC/GEJC)

pdf

Real-world safety of trastuzumab deruxtecan with gastric cancer: All patient post-marketing surveillance study in Japan

pdf

Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma

pdf

A single arm phase II trial of trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER

pdf

CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No